SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Alnaim, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alnaim, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Therapeutic drug monitoring of cancer chemotherapy

Lamya Alnaim, PharmD

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh, KSA 11495, Saudia Arabia, lamya.alnaim{at}gmail.com

Therapeutic drug monitoring is not routinely used for chemotherapy agents. There are Several reasons, but one major drawback is the lack of established therapeutic Concentration ranges. Combination chemotherapy makes the establishment of Therapeutic ranges for individual drugs difficult, the concentration-effect relationship for a single drug may not be the same as when that drug is used in a drug combination. Pharmacokinetic optimization protocols for many classes of cytotoxic compounds exist in specialized centers, and some of these protocols are now part of large multicentre trials. Nonetheless, TDM clearly has the potential to improve the clinical use of chemotherapy gents, most of which have very narrow therapeutic indices and highly variable pharmacokinetics. A substantial body of literature accumulating during the past 15 years demonstrates relationships between systemic exposure to various chemotherapy agents and their toxic or therapeutic effects. This article reviews TDM concepts in addition to tools based on pharmacokinetic modeling of chemotherapy agents. The administered dose of chemotherapy agents is sometimes adjusted individually using either a priori or a posteriori methods. These models can only be applied by using the same dose and schedule as the original study. Bayesian estimation offers more flexibility in blood sampling times and, owing to its precision and to the amount of information provided is the method of choice for ensuring that a given patient benefits from the desired systemic exposure. Moreover, the role and application of Pharmacogenetics as a tool for individualizing chemotherapy is discussed highlighting the agents and mechanisms that have been well studied and defined and their relevance to clinical practice. Finally, this paper address issues critical to the optimal use of TDM in a clinical setting, and the role of clinical pharmacist in this regard. In addition, it discusses future developments in this field that can contribute to improving cancer chemotherapy In terms of patient outcome and survival. J Oncol Pharm Practice (2007) 13: 207—221.

Key Words: therapeutic drug monitoring • chemotherapy • chemotherapy optimization

References

  • Rodman JH, Evans WE Targeted systemic exposure for pediatric cancer therapy. In: D'Argenio D. ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. 1991; New York, Plenum Press, 1991: 177—83.
  • Spector R., Park GD, Johnson GF, Vesell ES Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345—53.[Medline] [Order article via Infotrieve]
  • Reynolds DJM, Aronson JK Making the most of plasma drug concentration measurements. Br Med J 1993; 306: 48—51.[Free Full Text]
  • Evans WE, Relling MV Clinical pharmacokinetics— pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16: 327—36.[Medline] [Order article via Infotrieve]
  • Masson E., Zamboni WC Pharmacokinetic optimization of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997; 32: 324—43.[Medline] [Order article via Infotrieve]
  • Galpin AJ, Evans WE Therapeutic drug monitoring in cancer management. Clin Chem 1993; 39: 2419—30. 7 DeVita VT Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA. eds. Cancer. Principles and Practice of Oncology 1997; fifth edn, Philadelphia, Lippincott, 1997: 333—47.
  • Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987; 13: 205—27.[Medline] [Order article via Infotrieve]
  • Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520—28.[Abstract/Free Full Text]
  • Milano G., Roman P., Khater P., Frenay M., Renee N., Namer M. Dose versus pharmacokinetics for predicting tolerance to 5 day continuous infusion of 5-FU. Int J Cancer 1988; 41: 537—41.[Medline] [Order article via Infotrieve]
  • Milano G., Etienne MC, Renee N. et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994; 15: 1291—95.
  • Santini J., Milano G., Thyss A. et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989; 59: 287—90.[Medline] [Order article via Infotrieve]
  • Joel S., O'Byrne Penson K., Papamichael R. et al. A randomized concentration-controlled comparison of standard (5-day) vs. 260 A. Rousseau and P. Marquet prolonged (15-day) infusions of etoposide phosphate in small cell lung cancer. Ann Oncol 1998; 11: 1205—11.
  • Chatelut E., Pivot X., Otto J. et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000; 36: 264—69.[CrossRef][Medline] [Order article via Infotrieve]
  • Pignon T., Lacarelle B., Duffaud F. et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33: 420—24.[Medline] [Order article via Infotrieve]
  • Gamelin E., Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer — status of the art. Crit Rev Oncol Hematol 1999; 30: 71—79.[Medline] [Order article via Infotrieve]
  • Joel SP, Ellis P., O'Byrne K. et al. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol 1996; 14: 1903—12.[Abstract/Free Full Text]
  • Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol 2001; 52: 75—87.[CrossRef]
  • Rousseau A., Marquet P., Debord J., Sabot C., Lachâtre G. Adaptive control methods for dose individualization of anticancer agents. Clin Pharmacokinet 2000; 38: 315—53.[CrossRef][Medline] [Order article via Infotrieve]
  • Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281—88.[Medline] [Order article via Infotrieve]
  • Ratain MJ Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol 1992; 19: 8—13.[Medline] [Order article via Infotrieve]
  • Ratain MJ Pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA. eds. Cancer. Principles and Practice of Oncology 1997; fifth edn, Philadelphia, Lippincott, 1997: 375—85.
  • Hryniuk WM, Figueredo A., Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14: 3—11.[Free Full Text]
  • Frei E., Canellos GP Dose. A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585—94.[CrossRef][Medline] [Order article via Infotrieve]
  • Evans WE Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut 1988; 56: 241—48.[CrossRef][Medline] [Order article via Infotrieve]
  • Delepine N., Delepine G., Jasmin C., Desbois JC, Cornille H., Mathe G. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988; 42: 257—62.[Medline] [Order article via Infotrieve]
  • Bacci G., Ferrari S., Delepine N. et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16: 658—63.[Abstract]
  • Collins JM, Zaharko DS, Dedrick RL, Chabner BA Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986; 70: 73—80.[Medline] [Order article via Infotrieve]
  • EORTC. Pharmacokinetics and metabolism group. Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 1987; 23: 1083—87.[CrossRef][Medline] [Order article via Infotrieve]
  • Evans WE, Rodman JH, Relling MV, Crom WR, Rivera GK, Pratt CB, Crist WM Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Med Pediatr Oncol 1991; 19: 153—59.[Medline] [Order article via Infotrieve]
  • Evans WE Alternative approaches for phase I studies of anticancer drugs: a role for therapeutic drug monitoring. Ther Drug Monit 1993; 15: 492—97.[Medline] [Order article via Infotrieve]
  • Workman P., Graham MA Pharmacokinetics and cancer chemotherapy. Eur J Cancer 1994; 30A: 706—10.[CrossRef]
  • Evans WE, Petros WP, Relling MV, Crom WR, Madden T., Rodman JH, Sunderland M. Clinical pharmacology of cancer chemotherapy in children. Pediatr Clin North Am 1989; 36: 1199—230.[Medline] [Order article via Infotrieve]
  • Knoester PD, Underberg WJM, Beijnen JH Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients [Review]. Anticancer Res 1993; 13: 1795—808.[Medline] [Order article via Infotrieve]
  • Plunkett W., Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol 1993; 20: 50—63.[Medline] [Order article via Infotrieve]
  • Rodman JH, Relling MV, Stewart CF, Synold TW, McLeod H., Kearns C. et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993; 20: 18—29.[Medline] [Order article via Infotrieve]
  • Ratain MJ, Schilsky RL, Conley BA, Egorin MJ Pharmacodynamics in cancer therapy. JClin Oncol 1990; 8: 1739—53.
  • Graf N., Winkler K., Betlemovic M., Fuchs N., Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443—51.[Abstract]
  • Graves DA, Locke CS Jr, Muir KT, Miller RP The influence of assay variability on pharmacokinetic parameter estimation. JPharmacokinet Biopharm 1989; 17: 571—92.[CrossRef]
  • Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A., Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985; 45: 6502—06.[Abstract/Free Full Text]
  • Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748—56.[Abstract]
  • Newell DR, Pearson ADJ, Balmanno K. et al. Carboplatin pharmacokinetics in children: the development of a paediatric dosing formula. J Clin Oncol 1993; 11: 2314—23.[Abstract/Free Full Text]
  • Chatelut E., Canal P., Brunner V. et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573—80.[Abstract/Free Full Text]
  • Benezet S., Guimbaud R., Chatelut E., Chevreau C., Bugat R., Canal P. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Ann Oncol 1997; 6: 607—09.
  • Graf N., Winkler K., Betlemovic M., Fuchs N., Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443—51.[Abstract]
  • Pignon T., Lacarelle B., Duffaud F. et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33: 420—24.[Medline] [Order article via Infotrieve]
  • Odoul F., Le Guellec C., Lamagnere JP et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol 1999; 13: 595—604.[Medline] [Order article via Infotrieve]
  • Fety R., Rolland F., Barberi-Heyob M. et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorourzacil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 2039—45.[Abstract]
  • Gallo JM, Laub PB, Rowinski EK, Grochow LB, Baker SD Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000; 18: 2459—67.[Abstract/Free Full Text]
  • Monarzeri A., Boucaud M., Lokiec F. et al. Population pharmacokinetics of topotecan: intra-individual variability in total drug. Cancer Chemother Pharmacol 2000; 46: 375—81.[CrossRef][Medline] [Order article via Infotrieve]
  • Huitema AD, Mathot RA, Tibben MM, Schellens JH, Rodenhuis S., Beijnen JH Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 2000; 67: 621—30.[CrossRef][Medline] [Order article via Infotrieve]
  • Minami H., Beijnen JH, Verweij J., Ratain MJ Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res 1996; 2: 43—46.[Abstract/Free Full Text]
  • Stromgren AS, Sorensen BT, Jakobsen P., Jakobsen A. A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 1993; 32: 226—30.[CrossRef][Medline] [Order article via Infotrieve]
  • Ratain MJ, Robert J., Van Der Vijgh WJ Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 1991; 9: 871—76.[Abstract]
  • Sorensen BT, Stromgren A., Jakobsen P., Jakobsen A. A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993; 31: 324—27.[CrossRef][Medline] [Order article via Infotrieve]
  • Miyazaki M., Fujiwara Y., Takahashi T. et al. Limited-sampling models for estimation of the carboplatin area under the curve. Anticancer Res 1997; 17: 4571—75.[Medline] [Order article via Infotrieve]
  • Egorin MJ, Forrest A., Belani CP, Ratain MJ, Abrams JS, Van Echo DA A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 1989; 491: 3129—33.
  • Mick R., Gupta E., Vokes VV, Ratain MJ Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 1996; 14: 2012—19.[Abstract/Free Full Text]
  • Beal SL, Sheiner LB (Eds.) NONMEM. Users Guides. University of California, San Francisco, CA, 1994.
  • Karlsson MO, Jonsson EN, Wiltse CG, Wade JR Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998; 26: 207—45.[CrossRef][Medline] [Order article via Infotrieve]
  • Mallet A. A maximum likelihood estimation method for random coefficient regression. Biometrika 1986; 73: 645—56.[Abstract/Free Full Text]
  • Schumitsky A. Nonparametric EM algorithms for estimating prior distributions. App Math Comput 1991; 45: 141—57.
  • Jelliffe RW, Schumitzky A., Van Guilder M., Jiang F. Manual for the USC*Pack Collection of PC Programs. Laboratory of Applied Pharmacokinetics, School of Medicine 1995; Los Angeles, CA, University of Southern California, 1995.
  • Jelliffe RW, Schumitzky A., Bayard D. et al. Model-based, goal oriented individualized drug therapy. Clin Pharmacokinet 1998; 34: 57—77.[CrossRef][Medline] [Order article via Infotrieve]
  • Iliadis A., Bachir-Raho M., Bruno R., Favre R. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J Pharmacokinet Biopharm 1985; 13: 101—15.[CrossRef][Medline] [Order article via Infotrieve]
  • Sabot C., Debord J., Roullet B. et al. Bayesian estimation and population pharmacokinetic parameters of high dose methotrexate in osteosarcoma. Clin Res Reg Affairs 1993; 10: 233—41.[CrossRef]
  • Sabot C., Debord J., Roullet B., Marquet P., Merle L., Lachatre G. Comparison of 2- and 3-compartment models for Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33: 164—69.[Medline] [Order article via Infotrieve]
  • Pignon T., Lacarelle B., Duffaud F. et al. Dosage adjustment of high dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions. Ther Drug Monit 1995; 17: 164—69.
  • Peng B., Boddy AV, Cole M. et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer 1995; 31: 1804—10.[CrossRef]
  • Johansen MJ, Madden T., Mehra RC et al. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 1997; 15: 1481—91.[Abstract]
  • Doz F., Urien S., Chatelut E. et al. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children. Cancer Chemother Pharmacol 1998; 42: 250—54.[CrossRef][Medline] [Order article via Infotrieve]
  • Guillet P., Monjanel S., Nicoara A. et al. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h. Cancer Chemother Pharmacol 1997; 40: 143—49.[CrossRef][Medline] [Order article via Infotrieve]
  • Favre R., Charbit M., Rinaldi Y., Iliadis A., Cano JP, Carcassonne Y. La pharmacocine'tique dans les e'tudes de phase IV pour la pre'vision du sche'ma the'rapeutique. Bull Cancer 1988; 75: 541—50.[Medline] [Order article via Infotrieve]
  • Evene E., Chatelut E., Tranchand B. et al. Estimation bayesienne des parametres pharmacocine'tiques de 1'e'toposide. Bull Cancer 1997; 84: 699—703.[Medline] [Order article via Infotrieve]
  • Tranchand B., Amsellem C., Chatelut E. et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999; 43: 316—22.[CrossRef][Medline] [Order article via Infotrieve]
  • Rodman JH, Furman WL, Sunderland M., Rivera G., Evans WE Escalating teniposide systemic exposure to increase dose intensity for paediatric cancer patients. J Clin Oncol 1993; 11: 287—93.[Abstract/Free Full Text]
  • Launay MC, Milano G., Iliadis A., Frenay M., Namer N. A limited sampling procedure for estimating Adriamycin pharmacokinetics in cancer patients. Br J Cancer 1989; 60: 89—92.[Medline] [Order article via Infotrieve]
  • Bressolle F., Ray P., Jacquet JM et al. Bayesian estimation of doxorubicin pharmacokinetic parameters. Cancer Chemother Pharmacol 1991; 29: 53—60.[CrossRef][Medline] [Order article via Infotrieve]
  • Marchiset-Leca D., Leca FR, Galeani A., Noble A., Iliadis A. A limited sampling strategy for the study of pirarubicin pharmacokinetics in human. Cancer Chemother Pharmacol 1995; 36: 233—38.[Medline] [Order article via Infotrieve]
  • Yamamoto N., Tamura T., Karato A. et al. CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn J Cancer Res 1994; 85: 972—77.[CrossRef]
  • Nakashima H., Lieberman R., Karato A. et al. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration time curve monitoring. Ther Drug Monit 1995; 17: 221—29.[Medline] [Order article via Infotrieve]
  • Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996; 14: 1504—11.[Abstract/Free Full Text]
  • Crom WR, de Graaf SS, Synold T. et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994; 125: 642—49.[CrossRef][Medline] [Order article via Infotrieve]
  • Sabot C., Marquet P., Debord J., Carpentier N., Merle L., Lachâtre G. Bayesian pharmacokinetic estimation of vinoreline in non-small lung cancer patients. Eur J Clin Pharmacol 1998; 54: 171—75.[CrossRef][Medline] [Order article via Infotrieve]
  • Gauvin A., Pinguet F., Culine S., Astre C., Gomeni R., Bressolle F. Bayesin estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000; 6: 2690—95.[Abstract/Free Full Text]
  • Jodrell DI, Reyno LM, Sridhara R. et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 1994; 12: 166—75.[Abstract]
  • Eisenberger MA, Sinibaldi VJ, Reyno LM et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995; 13: 2174—86.[Abstract/Free Full Text]
  • Nguyen L., Tranchand B., Puozzo C., Variol P. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002; 53: 459—68.[CrossRef][Medline] [Order article via Infotrieve]
  • Variol P., Nguyen L., Tranchand B., Puozzo C. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 2002; 58: 467—76.[CrossRef][Medline] [Order article via Infotrieve]
  • Urien S., Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004; 57: 756—63.[CrossRef][Medline] [Order article via Infotrieve]
  • de Jongh FE, Gallo JM, Shen M., Verweij J., Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004; 54: 105—12.[Medline] [Order article via Infotrieve]
  • Slaviero KA, Clarke SJ, McLachlan AJ, Blair EYL, Rivory LP Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2003; 57: 44—53.[CrossRef]
  • Launay-Iliadis MC, Bruno R., Cosson V., Vergniol JC et al. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995; 37: 47—54.[Medline] [Order article via Infotrieve]
  • Falcone A., Pfanner E., Cianci C. et al. Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine based chemotherapy. Cancer 1995; 75: 440—43.[CrossRef][Medline] [Order article via Infotrieve]
  • Odoul F., Le Guellec C., Lamagnère JP et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic approach. Fundam Clin Pharmacol 1999; 13: 595—604.[Medline] [Order article via Infotrieve]
  • Ensom MH, Davis GA, Cropp CD et al. Clinical pharmacokinetics in the 21st century. Clin Pharmacokinet 1998; 34: 265—79.[CrossRef][Medline] [Order article via Infotrieve]
  • Evans WE, Relling MV, Rodman JH et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499—505.[Abstract/Free Full Text]
  • Fety R., Rolland F., Barberi-Heyob M. et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 2039—45.[Abstract]
  • Evans WE, McLeod HL Pharmacogenomics — drug disposition, drag targets, and side effects. N Engl J Med 2003; 348: 538—49.[Free Full Text]
  • Nagasubramanian R., Innocenti F., Ratain MJ Pharmacogenetics in cancer treatment. Annu Rev Med 2003; 54: 437—52.[CrossRef][Medline] [Order article via Infotrieve]
  • Marsh S., McLeod HL Cancer pharmacogenetics. Br J Cancer 2004; 90: 8—11.[CrossRef][Medline] [Order article via Infotrieve]
  • Houyau P., Gay C., Chatelut E. et al. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency [letter]. J Natl Cancer Inst 1993; 85: 1602—03.[Free Full Text]
  • Meinsma R., Fernandez-Salguero P., van Kulenberg AB et al. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995; 14: 1—6.[Medline] [Order article via Infotrieve]
  • Takai S., Fernandez-Salguero P., Kimura S. et al. Assignment of the human dihydropymidine dehydrogenase gene to chromosome region 1p22 by fluorescence in situ hybridisation. Genomics 1994; 24: 613—14.[CrossRef][Medline] [Order article via Infotrieve]
  • Albin N., Jonhson MR, Shahinian H. et al. Initial characterization of the molecular defect in human dihydropyrimidine dehydrogenase deficiency. Proc Am Assoc Cancer Res 1995; 36: 211.
  • Topic Elizabeta Pharmacogenetic and Tumour Drugs — 2005 http://www.ifcc.org/ejifcc/vol16no2/160206200512.htm
  • Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329—39.[CrossRef][Medline] [Order article via Infotrieve]
  • Lennard L., Lilleyman JS, Van Loon J. et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225—29.[CrossRef][Medline] [Order article via Infotrieve]
  • Klemetsdal B., Tollefsen E., Loennechen T. et al. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992; 51: 24—31.[Medline] [Order article via Infotrieve]
  • Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T., Schuetz JD et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279—90.[CrossRef][Medline] [Order article via Infotrieve]
  • Chabot GG Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33: 245—59.[Medline] [Order article via Infotrieve]
  • Iyer L., King CD, Whitington PR et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847—54.[Medline] [Order article via Infotrieve]
  • Ando Y., Saka H., Asai G. et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9: 845—47.[Abstract/Free Full Text]
  • Wasserman E., Myara A., Lokiec F. et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. J Clin Invest 1997; 8: 1049—51.
  • Canal P., Chatelut E., Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56: 1019—38.[CrossRef][Medline] [Order article via Infotrieve]
  • Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 1985; 76: 907—12.[Medline] [Order article via Infotrieve]
  • Marquet P., Lachatre G. Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology. J Chromatogr B 1999; 733: 93—118.[CrossRef]
  • Hon YY, Evans WE Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44: 388—400.[Abstract/Free Full Text]
  • Maxwell R. New techniques in the pharmacokinetic analysis of cancer drugs: III. Nuclear magnetic resonance. Cancer Surv 1993; 17: 415—23.
  • Ranson MR, Scarffe JH Population and Bayesian pharmacokinetics in oncology. Clin Oncol 1994; 6: 254—60.[CrossRef]
  • Masson A., Zamboni WC Pharmacokinetic optimization of cancer chemotherapy: effects on outcomes. Clin Pharmacokinet 1997; 32: 324—43.[Medline] [Order article via Infotrieve]
  • Bellissant E., Sébille V., Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modeling. Clin Pharmacokinet 1998; 35: 151—66.[CrossRef][Medline] [Order article via Infotrieve]
  • Vozeh S., Steimer JL, Rowland M. et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30: 81—93.[Medline] [Order article via Infotrieve]
  • Levy G. Predicting effective drug concentrations for individual patients: determinants of pharmacodynamic variability. Clin Pharmacokinet 1998; 34: 323—33.[CrossRef][Medline] [Order article via Infotrieve]
  • Bruguerolle B. Chronopharmacokinetics: current status. Clin Pharmacokinet 1998; 35: 83—94.[CrossRef][Medline] [Order article via Infotrieve]
  • Bressolle F., Joulia JM, Pinguet F., Ychou M. et al. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 1999; 44: 295—302.[CrossRef][Medline] [Order article via Infotrieve]
  • Yates CR, Pui CH, Evans WE Pharmacodynamic monitoring of cancer chemotherapy: childhood acute lymphoblastic as a model. Ther Drug Monit 1998; 20: 453—8.[CrossRef][Medline] [Order article via Infotrieve]
  • Karlsson MO, Molnar V., Bergh J. et al. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998; 63: 11—25.[CrossRef][Medline] [Order article via Infotrieve]
  • Minami H., Sasaki Y., Saijo N. et al. Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 1998; 64: 511—21.[CrossRef][Medline] [Order article via Infotrieve]

Journal of Oncology Pharmacy Practice, Vol. 13, No. 4, 207-221 (2007)
DOI: 10.1177/1078155207081133
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Alnaim, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alnaim, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement